According to its lodgement release, the company comes with 30 years of experience in China’s pharmaceutical market, particularly in clinical demand-oriented product identification and management as well as clinical development and commercialisation.
China Medical System Holdings, a Hong Kong-listed pharmaceutical company, is eyeing a secondary listing on the Mainboard of the Singapore Exchange (SGX) in July this year.
The company has been listed on the Main Board of the Stock Exchange of Hong Kong (HKEX) since 2010 and was included in the Hang Seng Large-Mid Cap (Investable) Index and Hang Seng Innovative Drug Index since 2020 and 2023 respectively.
